Literature DB >> 15366430

Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study).

Michael Phillips1, John P Boehmer, Renee N Cataneo, Taseer Cheema, Howard J Eisen, John T Fallon, Peter E Fisher, Alan Gass, Joel Greenberg, Jon Kobashigawa, Donna Mancini, Barry Rayburn, Mark J Zucker.   

Abstract

BACKGROUND: We evaluated a new marker of heart transplant rejection, the breath methylated alkane contour (BMAC). Rejection is accompanied by oxidative stress that degrades membrane polyunsaturated fatty acids, evolving alkanes and methylalkanes, which are excreted in the breath as volatile organic compounds (VOCs).
METHODS: Breath VOC samples (n = 1,061) were collected from 539 heart transplant recipients before scheduled endomyocardial biopsy. Breath VOCs were analyzed by gas chromatography and mass spectroscopy, and BMAC was derived from the abundance of C4-C20 alkanes and monomethylalkanes. The "gold standard" of rejection was the concordant set of International Society for Heart and Lung Transplantation (ISHLT) grades in biopsies read by 2 reviewers.
RESULTS: Concordant biopsies were: Grade 0, 645 of 1,061 (60.8%); 1A, 197 (18.6%); 1B, 84 (7.9%); 2, 93 (8.8%); and 3A, 42 (4.0%). A combination of 9 VOCs in the BMAC identified Grade 3 rejection (sensitivity 78.6%, specificity 62.4%, cross-validated sensitivity 59.5%, cross-validated specificity 58.8%, positive predictive value 5.6%, negative predictive value 97.2%). Site pathologists identified the same cases with sensitivity of 42.4%, specificity 97.0%, positive predictive value 45.2% and negative predictive value 96.7%.
CONCLUSIONS: A breath test for markers of oxidative stress was more sensitive and less specific for Grade 3 heart transplant rejection than a biopsy reading by a site pathologist, but the negative predictive values of the 2 tests were similar. A screening breath test could potentially identify transplant recipients at low risk of Grade 3 rejection and reduce the number of endomyocardial biopsies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15366430     DOI: 10.1016/j.healun.2003.07.017

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  21 in total

1.  A comparison of myocardial perfusion and rejection in cardiac transplant patients.

Authors:  Andrew L Rivard; Cory M Swingen; Donnevan Blake; Andrea S Huang; Pooja Kanth; Grete F Thomsen; Erin J Cordova; Leslie W Miller; Richard W Bianco; Norbert Wilke
Journal:  Int J Cardiovasc Imaging       Date:  2007-01-06       Impact factor: 2.357

2.  Breath metabolome of mice infected with Pseudomonas aeruginosa.

Authors:  Giorgia Purcaro; Mavra Nasir; Flavio A Franchina; Christiaan A Rees; Minara Aliyeva; Nirav Daphtary; Matthew J Wargo; Lennart K A Lundblad; Jane E Hill
Journal:  Metabolomics       Date:  2019-01-07       Impact factor: 4.290

Review 3.  Cardiovascular biomarkers in exhaled breath.

Authors:  Frank S Cikach; Raed A Dweik
Journal:  Prog Cardiovasc Dis       Date:  2012 Jul-Aug       Impact factor: 8.194

Review 4.  The clinical potential of exhaled breath analysis for diabetes mellitus.

Authors:  Timothy Do Chau Minh; Donald Ray Blake; Pietro Renato Galassetti
Journal:  Diabetes Res Clin Pract       Date:  2012-03-10       Impact factor: 5.602

5.  Noninvasive measurement of plasma glucose from exhaled breath in healthy and type 1 diabetic subjects.

Authors:  Timothy D C Minh; Stacy R Oliver; Jerry Ngo; Rebecca Flores; Jason Midyett; Simone Meinardi; Matthew K Carlson; F Sherwood Rowland; Donald R Blake; Pietro R Galassetti
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-04-05       Impact factor: 4.310

6.  Blood and breath levels of selected volatile organic compounds in healthy volunteers.

Authors:  Paweł Mochalski; Julian King; Martin Klieber; Karl Unterkofler; Hartmann Hinterhuber; Matthias Baumann; Anton Amann
Journal:  Analyst       Date:  2013-02-25       Impact factor: 4.616

7.  Noninvasive detection of lung cancer by analysis of exhaled breath.

Authors:  Amel Bajtarevic; Clemens Ager; Martin Pienz; Martin Klieber; Konrad Schwarz; Magdalena Ligor; Tomasz Ligor; Wojciech Filipiak; Hubert Denz; Michael Fiegl; Wolfgang Hilbe; Wolfgang Weiss; Peter Lukas; Herbert Jamnig; Martin Hackl; Alfred Haidenberger; Bogusław Buszewski; Wolfram Miekisch; Jochen Schubert; Anton Amann
Journal:  BMC Cancer       Date:  2009-09-29       Impact factor: 4.430

8.  Detection of lung cancer using weighted digital analysis of breath biomarkers.

Authors:  Michael Phillips; Nasser Altorki; John H M Austin; Robert B Cameron; Renee N Cataneo; Robert Kloss; Roger A Maxfield; Muhammad I Munawar; Harvey I Pass; Asif Rashid; William N Rom; Peter Schmitt; James Wai
Journal:  Clin Chim Acta       Date:  2008-03-03       Impact factor: 3.786

9.  Assessment of the exhalation kinetics of volatile cancer biomarkers based on their physicochemical properties.

Authors:  Anton Amann; Pawel Mochalski; Vera Ruzsanyi; Yoav Y Broza; Hossam Haick
Journal:  J Breath Res       Date:  2014-02-24       Impact factor: 3.262

Review 10.  Current Challenges in Volatile Organic Compounds Analysis as Potential Biomarkers of Cancer.

Authors:  Kamila Schmidt; Ian Podmore
Journal:  J Biomark       Date:  2015-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.